1Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 2009, 49(5 Suppl):S 103-111.
2Cootksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepattitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 2003, 10: 298-305.
3Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic heaptitis B. N Engl J Meal, 2005, 352: 2682-2695.
4Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351: 1206-1217.
5Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg- positive chronic hepatitis B: a randomised trial. Lancet, 2005, 365: 123-129.
6European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol, 2009, 50: 227-242.
7Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut, 2007, 56: 699-705.
8Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg positive chronic hepatitis B. Hepatology, 2008, 47: 428-434.
9Buster EH, Flind HJ, Simsek H, et al. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up strdy in chronic hepatitis B patients. Am J Gastroenterol, 2009[Epub ahead of print].
10Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009, 49: 1151-1157.
